Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370095 · ClinicalTrials.gov registry record · Phase 2
Treprostinil Sodium Inhalation for Patients At High Risk for ARDS
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT02370095 is a Phase 2 study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 14 participants.
The verdict
NCT02370095, a Phase 2 study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressing lung disease caused by a number of factors including pneumonia, sepsis and acute trauma that leads to reduced lung function and breathlessness. There are no pharmacological treatments approved for the treatment of ARDS. This pilot trial will study the safety and efficacy of Treprostinil sodium by inhalation for preventing the progression of acute hypoxemic respiratory failure to positive pressure ventilation and/or ARDS in patients at high risk.
Interventions
- DRUG Placebo
- DRUG Treprostinil Inhalation Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02370095
The ClinicalTrials.gov registry entry for NCT02370095 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02370095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02370095 about?
NCT02370095 is a clinical study titled "Treprostinil Sodium Inhalation for Patients At High Risk for ARDS". Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressing lung disease caused by a number of factors including pneumonia, sepsis and acute trauma that leads to reduced lung function and breathlessness. There are no pharmacological treatments approved for the treatment of ARDS. This pilot t...
What is the current status of trial NCT02370095?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2015-02. Estimated completion is 2017-11-07.
What interventions are being tested in trial NCT02370095?
The interventions under investigation include: Placebo (DRUG), Treprostinil Inhalation Solution (DRUG).
Who is sponsoring clinical trial NCT02370095?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.